200 related articles for article (PubMed ID: 21640372)
1. Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis.
Lee YY; Kim TJ; Kim MJ; Kim HJ; Song T; Kim MK; Choi CH; Lee JW; Bae DS; Kim BG
Gynecol Oncol; 2011 Sep; 122(3):541-7. PubMed ID: 21640372
[TBL] [Abstract][Full Text] [Related]
2. Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?
Kajiyama H; Mizuno M; Shibata K; Umezu T; Suzuki S; Yamamoto E; Mitsui H; Sekiya R; Niimi K; Kawai M; Nagasaka T; Kikkawa F
Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():305-10. PubMed ID: 25203309
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.
Mackay HJ; Brady MF; Oza AM; Reuss A; Pujade-Lauraine E; Swart AM; Siddiqui N; Colombo N; Bookman MA; Pfisterer J; du Bois A;
Int J Gynecol Cancer; 2010 Aug; 20(6):945-52. PubMed ID: 20683400
[TBL] [Abstract][Full Text] [Related]
4. Clear cell carcinoma of the ovary: a review of the literature.
del Carmen MG; Birrer M; Schorge JO
Gynecol Oncol; 2012 Sep; 126(3):481-90. PubMed ID: 22525820
[TBL] [Abstract][Full Text] [Related]
5. Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: Results from a single-center Taiwanese study.
Ku FC; Wu RC; Yang LY; Tang YH; Chang WY; Yang JE; Wang CC; Jung SM; Lin CT; Chang TC; Chao A; Lai CH
J Formos Med Assoc; 2018 Feb; 117(2):117-125. PubMed ID: 28389144
[TBL] [Abstract][Full Text] [Related]
6. The clinical value of surgeons' efforts of preventing intraoperative tumor rupture in stage I clear cell carcinoma of the ovary: A Korean multicenter study.
Suh DH; Park JY; Lee JY; Kim BG; Lim MC; Kim JW; Bae DS; Park SY; Nam JH; Kim K; No JH; Kim YB
Gynecol Oncol; 2015 Jun; 137(3):412-7. PubMed ID: 25868967
[TBL] [Abstract][Full Text] [Related]
7. Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types.
Higashi M; Kajiyama H; Shibata K; Mizuno M; Mizuno K; Hosono S; Kawai M; Nakanishi T; Nagasaka T; Kikkawa F
Gynecol Oncol; 2011 Dec; 123(3):474-8. PubMed ID: 21955484
[TBL] [Abstract][Full Text] [Related]
8. Long-term oncologic outcome and its prognostic indicators in reproductive-age women with ovarian clear-cell carcinoma.
Kajiyama H; Suzuki S; Yoshikawa N; Niimi K; Kawai M; Shibata K; Kikkawa F
Arch Gynecol Obstet; 2019 Sep; 300(3):717-724. PubMed ID: 31165243
[TBL] [Abstract][Full Text] [Related]
9. A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age.
Kajiyama H; Mizuno M; Shibata K; Umezu T; Suzuki S; Yamamoto E; Mitsui H; Sekiya R; Niimi K; Kawai M; Nagasaka T; Kikkawa F
Int J Clin Oncol; 2014 Oct; 19(5):921-7. PubMed ID: 24306200
[TBL] [Abstract][Full Text] [Related]
10. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
[TBL] [Abstract][Full Text] [Related]
12. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
Vogel TJ; Goodman MT; Li AJ; Jeon CY
Gynecol Oncol; 2017 Aug; 146(2):340-345. PubMed ID: 28596017
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Clinical Characteristic and Prognosis between Ovarian Clear Cell Carcinoma and Serous Carcinoma: A 10-Year Cohort Study of Chinese Patients.
Ye S; Yang J; You Y; Cao D; Huang H; Wu M; Chen J; Lang J; Shen K
PLoS One; 2015; 10(7):e0133498. PubMed ID: 26186453
[TBL] [Abstract][Full Text] [Related]
14. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases.
Han G; Gilks CB; Leung S; Ewanowich CA; Irving JA; Longacre TA; Soslow RA
Am J Surg Pathol; 2008 Jul; 32(7):955-64. PubMed ID: 18460981
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
16. Histological Tumor Type is Associated with One-Year Cause-Specific Survival in Women with Stage III-IV Epithelial Ovarian Cancer: A Surveillance, Epidemiology, and End Results (SEER) Database Population Study, 2004-2014.
Wu SG; Li FY; Lei J; Hua L; He ZY; Zhou J
Med Sci Monit; 2020 Feb; 26():e920531. PubMed ID: 32008036
[TBL] [Abstract][Full Text] [Related]
17. Does the primary route of spread have a prognostic significance in stage III non-serous epithelial ovarian cancer?
Sahin H; Meydanli MM; Sari ME; Yalcin I; Çoban G; Ozkan NT; Cuylan ZF; Erdem B; Gungorduk K; Akbayir Ö; Dede M; Salman MC; Güngör T; Ayhan A
J Ovarian Res; 2018 Mar; 11(1):21. PubMed ID: 29506569
[TBL] [Abstract][Full Text] [Related]
18. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in epithelial ovarian cancer: A population-based study.
Chang LC; Huang CF; Lai MS; Shen LJ; Wu FL; Cheng WF
PLoS One; 2018; 13(3):e0194993. PubMed ID: 29579127
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]